A randomised, placebo-controlled, double-blind, phase I/IIa clinical trial to evaluate the safety and immunogenicity of a candidate prophylactic DNA prime-rFPV boost HIV [HIV DNA vaccine] vaccination strategy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HIV DNA vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 27 Aug 2007 Biomarkers information updated
- 03 Nov 2005 New trial record.